Log in

Novus Therapeutics Stock Price, News & Analysis (NASDAQ:NVUS)

$0.54
+0.02 (+3.85 %)
(As of 10/14/2019 02:29 AM ET)
Today's Range
$0.51
Now: $0.54
$0.58
50-Day Range
$0.51
MA: $0.69
$0.79
52-Week Range
$0.50
Now: $0.54
$5.21
Volume97,266 shs
Average Volume59,057 shs
Market Capitalization$7.01 million
P/E RatioN/A
Dividend YieldN/A
Beta2.86
Novus Therapeutics, Inc, a pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is (OP-02), a surfactant-based combination drug product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology (OP-01) that could be used to deliver drugs into the ear, nose, and sinus cavities. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVUS
CUSIPN/A
Phone949-238-8090

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.54 per share

Profitability

Net Income$-14,060,000.00

Miscellaneous

EmployeesN/A
Market Cap$7.01 million
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable

Receive NVUS News and Ratings via Email

Sign-up to receive the latest news and ratings for NVUS and its competitors with MarketBeat's FREE daily newsletter.


Novus Therapeutics (NASDAQ:NVUS) Frequently Asked Questions

What is Novus Therapeutics' stock symbol?

Novus Therapeutics trades on the NASDAQ under the ticker symbol "NVUS."

How were Novus Therapeutics' earnings last quarter?

Novus Therapeutics Inc (NASDAQ:NVUS) issued its quarterly earnings results on Tuesday, August, 13th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($0.35). View Novus Therapeutics' Earnings History.

When is Novus Therapeutics' next earnings date?

Novus Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Novus Therapeutics.

What price target have analysts set for NVUS?

1 analysts have issued 1-year price targets for Novus Therapeutics' stock. Their forecasts range from $10.00 to $10.00. On average, they anticipate Novus Therapeutics' stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 1,751.5% from the stock's current price. View Analyst Price Targets for Novus Therapeutics.

What is the consensus analysts' recommendation for Novus Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novus Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Novus Therapeutics.

Has Novus Therapeutics been receiving favorable news coverage?

Press coverage about NVUS stock has trended negative recently, according to InfoTrie. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Novus Therapeutics earned a news sentiment score of -2.6 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Novus Therapeutics.

Are investors shorting Novus Therapeutics?

Novus Therapeutics saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 28,800 shares, an increase of 35.8% from the August 30th total of 21,200 shares. Based on an average daily volume of 67,600 shares, the short-interest ratio is presently 0.4 days. Approximately 0.2% of the shares of the company are sold short. View Novus Therapeutics' Current Options Chain.

Who are some of Novus Therapeutics' key competitors?

What other stocks do shareholders of Novus Therapeutics own?

Who are Novus Therapeutics' key executives?

Novus Therapeutics' management team includes the folowing people:
  • Mr. Gregory J. Flesher, CEO & Director (Age 49)
  • Dr. Catherine C. Turkel, Pres (Age 58)
  • Mr. Jon Kuwahara CPA, Sr. VP of Fin. & Admin. (Age 54)

How do I buy shares of Novus Therapeutics?

Shares of NVUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Novus Therapeutics' stock price today?

One share of NVUS stock can currently be purchased for approximately $0.54.

How big of a company is Novus Therapeutics?

Novus Therapeutics has a market capitalization of $7.01 million. The biopharmaceutical company earns $-14,060,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis. View Additional Information About Novus Therapeutics.

What is Novus Therapeutics' official website?

The official website for Novus Therapeutics is http://novustherapeutics.com/.

How can I contact Novus Therapeutics?

Novus Therapeutics' mailing address is 19900 MACARTHUR BLVD. SUITE 550, IRVINE CA, 92612. The biopharmaceutical company can be reached via phone at 949-238-8090 or via email at [email protected]


MarketBeat Community Rating for Novus Therapeutics (NASDAQ NVUS)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  211 (Vote Outperform)
Underperform Votes:  201 (Vote Underperform)
Total Votes:  412
MarketBeat's community ratings are surveys of what our community members think about Novus Therapeutics and other stocks. Vote "Outperform" if you believe NVUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/14/2019 by MarketBeat.com Staff

Featured Article: What is the G-20?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel